Neuropharmacology
Field of study
Follow Neuropharmacology on Notably News to receive short updates to your email — rarely!
We include updates on Adderall, Amphetamine, Lisdexamfetamine, Serotonin syndrome, Pseudoephedrine, Dextroamphetamine, Ephedrine, Depressant, Inhalant, Phenylpropanolamine, Glycerophosphorylcholine, Melatonin as a medication and supplement, Levoamphetamine, Effects of long-term benzodiazepine use, Pharmacology of ethanol, Psychiatric medication ... and more.
| 2024 |
Alcohol
The World Health Organization published a report detailing global mortality impacts, noting that four industries (tobacco, unhealthy food, fossil fuel, and alcohol) are responsible for at least a third of global deaths per year.
|
| 2023 |
Pharmacology of ethanol
A comprehensive study using a two-compartment model with Michaelis-Menten elimination kinetics was conducted, analyzing alcohol elimination data from 60 men and 12 women, ultimately finding statistically insignificant gender effects on maximal elimination rate.
|
| April 2023 |
Alcohol
World Health Organization (WHO) published a statement in The Lancet Public Health declaring that 'there is no safe amount of alcohol that does not affect health'.
|
| February 24 2023 |
Lisdexamfetamine
Patent protection for lisdexamfetamine expired in the United States.
|
| 2022 |
Lisdexamfetamine
A network meta-analysis found lisdexamfetamine was significantly effective as an antidepressant augmentation for treatment-resistant depression.
|
| 2022 |
Lisdexamfetamine
Became the 69th most commonly prescribed medication in the United States, with over 9 million prescriptions issued, indicating significant medical adoption and usage.
|
| 2019 |
Lisdexamfetamine
A systematic review concluded that lisdexamfetamine was the most effective treatment for adult ADHD, highlighting its significant clinical importance in managing the disorder.
|
| 2018 |
Lisdexamfetamine
First meta-analysis of randomized controlled trials of lisdexamfetamine for antidepressant augmentation was conducted, finding no significant improvement over placebo in depression rating scales.
|
| 2015 |
Lisdexamfetamine
FDA gave tentative approval to generic formulations of lisdexamfetamine.
|
| 2015 |
Alcohol
A comprehensive study revealed that alcohol and tobacco use combined resulted in over a quarter of a billion disability-adjusted life years, highlighting the significant global health burden of these substances.
|
| January 2015 |
Lisdexamfetamine
FDA approved lisdexamfetamine for the treatment of binge eating disorder in adults.
|
| February 2014 |
Lisdexamfetamine
Shire pharmaceutical company announced that late-stage clinical trials found Vyvanse (lisdexamfetamine) was not an effective treatment for depression, leading to discontinuation of development for this medical indication.
|
| 2012 |
Lisdexamfetamine
Lisdexamfetamine received approval for medical use in the European Union, expanding its availability as a treatment for ADHD and related conditions.
|
This contents of the box above is based on material from the Wikipedia articles Lisdexamfetamine, Alcohol (drug) & Pharmacology of ethanol, which are released under the Creative Commons Attribution-ShareAlike 4.0 International License.